Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 04/09/2007
Entire Document
 
 

2.03   Licensed Mouse Patent Field of Use” shall mean the breeding and use of MICE for LICENSEE’s own internal research purposes for drug development and characterization to develop therapeutic agents, compositions, and/or formulations to control hunger and/or feeding behavior. The Licensed Mouse Patent Field of Use specifically includes brain tissue, and more specifically brain slices including the arcuate nucleus, for analysis of the effects of potential therapeutic materials, compositions and formulations upon the defined neuronal circuits affecting feeding behavior and/or feelings of hunger or satiety. The Licensed Mouse Patent Field of Use specifically excludes DNA extracted from MICE, or the development or use of any cells, cell lines or subcellular fractions of MICE, particularly as a product for sale or distribution.
 
2.04   Licensed Mouse Patent Rights” shall mean [***].
 
2.05   Licensed Mouse Patent Territory” shall mean facilities operated by or on behalf of LICENSEE in the United States.
 
2.06   Licensed Screening Patent Field of Use” shall mean screening for drug development and characterization to develop therapeutic agents, compositions, and/or formulations to control hunger and/or feeding behavior for LICENSEE’s own internal research purposes.
 
2.07   Licensed Screening Patent Rights” shall mean:
2.07.1 [***], all divisions which claim priority to this application, and all patents issuing from such applications, divisions, and continuations, and in any reissues, reexaminations, and extensions of all such patents;
2.07.2 to the extent that the following contain one or more claims fully supported in 2.07.1 above: said claims (i) in continuations-in-part of 2.07.1 above; (ii) in all divisions and continuations of these continuations-in-part; (iii) in all patents issuing from such continuations-in-part, divisions, and continuations; and (iv) in any reissues, reexaminations, and extensions of all such patents; and
2.07.3 to the extent that the following contain one or more claims fully supported in 2.07.1 above: said claims in all counterpart foreign applications and patents to 2.07.1 and 2.07.2 above.
    Licensed Screening Patent Rights shall not include (2.07.2) or (2.07.3) above to the extent that they contain one or more claims directed to new matter that is not fully supported in (2.07.1) above. Nor shall Licensed Screening Patent Rights include any claims to a composition of matter.
 
2.08   “Licensed Screening Patent Territory” shall mean worldwide.
 
***   Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.